Galleon Pharmaceuticals, Inc.

États‑Unis d’Amérique

Retour au propriétaire

1-9 de 9 pour Galleon Pharmaceuticals, Inc. Trier par
Recheche Texte
Affiner par
Classe IPC
C07D 251/54 - Trois atomes d'azote 3
A01N 43/50 - Diazoles-1,3Diazoles-1,3 hydrogénés 1
A01N 43/78 - Thiazoles-1,3Thiazoles-1,3 hydrogénés 1
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide 1
A61K 31/425 - Thiazoles 1
Voir plus
Résultats pour  brevets

1.

NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME

      
Numéro d'application US2014025792
Numéro de publication 2014/151462
Statut Délivré - en vigueur
Date de dépôt 2014-03-13
Date de publication 2014-09-25
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Dax, Scott
  • Mencel, James Joseph
  • Ozola, Vita
  • Shubin, Kirill
  • Martjuga, Marina
  • Suna, Edgars

Abrégé

The present invention includes pyrimido[5,4-d]pyrimidines that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention.

Classes IPC  ?

  • A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
  • A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
  • C07D 257/12 - Cycles à six chaînons comportant quatre atomes d'azote

2.

NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME

      
Numéro d'application US2013070160
Numéro de publication 2014/078575
Statut Délivré - en vigueur
Date de dépôt 2013-11-14
Date de publication 2014-05-22
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Mannion, James C.
  • Dax, Scott L.
  • Golder, Francis John
  • Macintyre, Duncan Euan
  • Mcleod, James
  • Ozola, Vita
  • Suna, Edgars
  • Shubin, Kirill
  • Mencel, James Joseph
  • Peng, Sean X.

Abrégé

The present invention includes compositions that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention.

Classes IPC  ?

3.

NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

      
Numéro d'application US2013043052
Numéro de publication 2013/181217
Statut Délivré - en vigueur
Date de dépôt 2013-05-29
Date de publication 2013-12-05
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Mannion, James, C.
  • Dax, Scott, L.
  • Macintyre, Duncan, Euan
  • Golder, Francis, John
  • Mcleod, James, Francis

Abrégé

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

Classes IPC  ?

4.

COMPOSITIONS AND METHODS FOR TREATING BREATHING CONTROL DISORDERS OR DISEASES

      
Numéro d'application US2012040195
Numéro de publication 2012/166909
Statut Délivré - en vigueur
Date de dépôt 2012-05-31
Date de publication 2012-12-06
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Mannion, James, C.
  • Dax, Scott, L.
  • Woodward, Richard
  • Ozola, Vita

Abrégé

The present invention includes a method of treating a breathing control disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising (+)-ketodoxapram or a solvate thereof and a pharmaceutically acceptable carrier, wherein the composition is essentially free of (— )-ketodoxapram or a solvate thereof.

Classes IPC  ?

  • A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines

5.

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

      
Numéro d'application US2011062386
Numéro de publication 2012/074999
Statut Délivré - en vigueur
Date de dépôt 2011-11-29
Date de publication 2012-06-07
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Dax, Scott, L.
  • Woodward, Richard
  • Peng, Sean

Abrégé

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

Classes IPC  ?

  • C07D 251/54 - Trois atomes d'azote
  • A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine

6.

NOVEL METHODS FOR TREATING BREATHING DISORDERS OR DISEASES

      
Numéro d'application US2011057241
Numéro de publication 2012/054813
Statut Délivré - en vigueur
Date de dépôt 2011-10-21
Date de publication 2012-04-26
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Mannion, James, C.
  • Dax, Scott, L.
  • Woodward, Richard

Abrégé

The present invention includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising (+)-doxapram or a salt thereof, and a pharmaceutically acceptable earner, wherein the formulation is essentially free of (— )-doxapram or a salt thereof.

Classes IPC  ?

  • A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide

7.

ANALGESIC COMPOUNDS, COMPOSITIONS, AND USES THEREOF

      
Numéro d'application US2011027580
Numéro de publication 2011/112602
Statut Délivré - en vigueur
Date de dépôt 2011-03-08
Date de publication 2011-09-15
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Mannion, James, C.
  • Dax, Scott, L.

Abrégé

The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

Classes IPC  ?

8.

S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES

      
Numéro d'application US2009039351
Numéro de publication 2009/151744
Statut Délivré - en vigueur
Date de dépôt 2009-04-02
Date de publication 2009-12-17
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Mannion, James, C.
  • Dax, Scott, L.

Abrégé

The present invention is directed to mercapto-based and S- nitrosomercapto-based SNO compounds and their derivatives, and their use in treating a lack of normal breathing control, including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions.

Classes IPC  ?

  • A01N 43/50 - Diazoles-1,3Diazoles-1,3 hydrogénés

9.

S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES

      
Numéro d'application US2007021311
Numéro de publication 2008/066603
Statut Délivré - en vigueur
Date de dépôt 2007-10-03
Date de publication 2008-06-05
Propriétaire GALLEON PHARMACEUTICALS, INC. (USA)
Inventeur(s) Mannion, James, C.

Abrégé

The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a single compound which treats lack of normal breathing. In another aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In an aspect, a compound is an S-nitrosylating agent.

Classes IPC  ?

  • A61K 38/00 - Préparations médicinales contenant des peptides